Analyst Ratings for [PEN] Penumbra, Inc.

10/8/25	Upgrades	Hold Buy	X
PEN Penumbra Needham
$326
9/2/25	Initiated	Outperform	X
PEN Penumbra Evercore ISI
$300
1/21/25	Initiated	Buy	X
PEN Penumbra UBS
$305
12/17/24	Initiated	Outperform	X
PEN Penumbra Oppenheimer
$275
12/11/24	Upgrades	Eq Weight Overweight	X
PEN Penumbra Wells Fargo
$190 $275
9/18/24	Initiated	Buy	X
PEN Penumbra Stifel
$238
9/3/24	Initiated	Outperform	X
PEN Penumbra Leerink Partners
$263
7/31/24	Downgrades	Buy Neutral	X
PEN Penumbra Citigroup
$165 $178
7/31/24	Downgrades	Overweight Eq Weight	X
PEN Penumbra Wells Fargo
$289 $150
2/23/24	Downgrades	Overweight Neutral	X
PEN Penumbra JP Morgan
$284 $250
9/6/23	Initiated	Equal-Weight	X
PEN Penumbra Morgan Stanley
$265
7/19/23	Initiated	Outperform	X
PEN Penumbra Robert W. Baird
$375
3/29/23	Downgrades	Buy Hold	X
PEN Penumbra Needham
1/30/23	Initiated	Overweight	X
PEN Penumbra Piper Sandler
$275
11/4/22	Upgrades	Neutral Buy	X
PEN Penumbra Citigroup
$217 $212
10/12/22	Initiated	Buy	X
PEN Penumbra Jefferies
$230
10/5/22	Downgrades	Buy Neutral	X
PEN Penumbra Citigroup
$170 $217
9/9/22	Upgrades	Hold Buy	X
PEN Penumbra Needham
7/18/22	Initiated	Outperform	X
PEN Penumbra RBC Capital Mkts
$195
4/19/22	Initiated	Buy	X
PEN Penumbra Deutsche Bank
$250
3/8/22	Initiated	Hold	X
PEN Penumbra Needham
6/4/21	Upgrades	Neutral Buy	X
PEN Penumbra BTIG Research
$291
6/13/19	Reiterated	Buy	X
PEN Penumbra BofA/Merrill
$150 $180
5/30/19	Upgrades	Neutral Overweight	X
PEN Penumbra JP Morgan
5/21/19	Initiated	Outperform	X
PEN Penumbra William Blair
10/29/18	Resumed	Buy	X
PEN Penumbra BofA/Merrill
$36
10/8/18	Initiated	Outperform	X
PEN Penumbra RBC Capital Mkts
$174
2/21/18	Initiated	Outperform	X
PEN Penumbra William Blair

PEN Penumbra, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Penumbra, Inc. is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. It focuses on developing, manufacturing and marketing products for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. Its neuro products include Neurovascular Access, Neuro Thrombectomy (Ischemic Stroke), Neurovascular Embolization (Brain Aneurysms) and Neurosurgical Tools (Hemorrhagic Stroke). Its peripheral vascular products include Peripheral Vascular Embolization and Peripheral Thrombectomy.